Dwight Evans is spiking on Google today, which is a strange thing to write because the Bluesky posts driving the buzz are about a different Dwight Evans entirely: the Hall of Fame-caliber Red Sox right fielder with 67.2 career bWAR. The congressman from Philadelphia's 3rd district is, apparently, just borrowing the name recognition. Which is fine. What's less fine, if you're the kind of person who reads financial disclosures for fun, is that the sitting member of the House Ways and Means Committee has posted a 0-for-9 alpha record on disclosed trades in the past several months, sold General Dynamics stock before voting no on the FY2027 National Defense Authorization Act, and managed to sell Thermo Fisher Scientific in a period when his own committee has jurisdiction over healthcare policy. The calendar is doing a lot of work here.
The Wrong Dwight Evans
Seven Bluesky posts in the last 24 hours mention the name Dwight Evans. Every one of them is about the outfielder. One post notes his 67.2 bWAR ranks fourth in Red Sox franchise history, ahead of 19 Hall of Famers at his position. Another catalogs go-ahead grand slams against the Athletics going back to 1982.
The congressman from Pennsylvania is not being discussed on social media today. He is, however, being discussed here, because five stock trades filed in the last 90 days and a string of recent floor votes make for a more interesting read than box scores. Probably.
The Trades: Five Sales, Zero Winners
Here's what Blind Trust's full disclosure record on Evans shows: five sales filed between May 7 and June 10, 2026, all in the $1,000-to-$15,000 range. Not enormous positions. But the 30-day performance after each sale tells a consistent story, and the story is that Evans kept selling stocks that then went up.
Across nine scored trades in the full record, Evans has posted zero positive 30-day alpha outcomes. Zero. His mean 30-day alpha across the sample is negative 5.1 percent. To be clear about what that means: on average, the stocks he sold outperformed the S&P 500 by 5.1 points in the 30 days after he sold them. Nine times. Every single time.
The math:
- Quanta Services (PWR), sold May 7: negative 7.7% alpha in the 30 days after the sale.
- Thermo Fisher Scientific (TMO), sold May 7: negative 7.8% alpha. This one has a committee overlap flag (more on that below).
- Micron Technology (MU), sold March 24: negative 14.1% alpha. The single worst outcome in the scored sample.
- Intel (INTC), sold May 7: negative 1.5% alpha.
- American Tower (AMT), sold May 11: essentially flat alpha, the closest thing to a wash in the dataset.
- General Dynamics (GD), sold June 10: negative 0.4% alpha over 30 days.
To be precise about what this record is: it's the full scored sample, not a highlight reel of bad calls. This is all of them. 0-for-9. The batting average is.000 and the season is not over.
The Defense Vote and the Defense Sale
On June 10, Evans filed a sale of General Dynamics stock, the defense and aerospace contractor, in the $1,001-to-$15,000 range. Six weeks later, on July 22, he voted no on the National Defense Authorization Act for Fiscal Year 2027. The NDAA passed anyway.
The vote itself is unremarkable in isolation. Evans voted no on multiple NDAA amendments the same day, including a Boebert amendment on athletic career service obligations, a Grothman amendment requiring a report on cutting 200,000 Defense Department civilians, and a Harrigan amendment banning automated speed cameras on military installations. He was a consistent no across the board.
What's worth noting is the sequence. He sold a defense contractor. Then he voted against the defense bill. The Venn diagram of "sold GD" and "voted no on NDAA" is two overlapping circles. Whether the circles have anything to do with each other is a question the public record doesn't answer. The public record just draws the circles.
General Dynamics builds submarines, combat vehicles, and Gulfstream jets. The NDAA is the primary vehicle for setting the Pentagon's budget priorities. Evans is on Ways and Means, not Armed Services, so there's no committee-level conflict angle here. The trade and the vote are just two data points that happen to share a thematic ZIP code.
The One That Has a Flag on It
Of the five recent sales, one carries a committee overlap designation in the Blind Trust data: Thermo Fisher Scientific, sold May 7, in the $1,000-to-$15,000 range.
Thermo Fisher makes lab equipment, diagnostics tools, and life sciences instruments. It's a healthcare-adjacent name. Evans sits on the House Ways and Means Committee, specifically including the Health subcommittee. Healthcare is, in fact, in the actual remit of his committee. That's the flag.
The 30-day alpha on that sale: negative 7.8 percent. Meaning the stock outperformed the index by 7.8 points after he sold it. Whether his committee seat and his portfolio overlap in a way that carries any meaning is a judgment call the disclosure rules leave entirely to the reader. Evans was required to report the trade. He was not required to explain it, recuse himself from related healthcare legislation, or otherwise acknowledge that he sits on a health policy committee while holding and selling a health-sector stock.
That's the rule. Yes, really.
The Other Votes: Financial Privacy and Small Business Capital
Evans also voted no on two other bills that cleared the House in the last few weeks. On July 14, he voted against the Protecting Privacy in Purchases Act, which passed. On July 21, he voted against the Main Street Capital Access Act, which also passed. Both votes went against him.
The Protecting Privacy in Purchases Act sits in financial privacy territory. The Main Street Capital Access Act targets small business lending access. Ways and Means covers tax and trade, not banking regulation in the traditional sense, so neither vote carries a specific committee-level conflict angle for Evans. He's a Democrat voting no on Republican-majority bills. That's floor politics, not portfolio management.
Still: he voted no on the Main Street Capital Access Act on July 21. He'd sold American Tower on May 11 and General Dynamics on June 10. The vote-to-trade overlap log for Evans shows no formal overlaps flagged in the Blind Trust data. The votes and trades exist in separate columns of the spreadsheet.
What the Alpha Record Actually Tells You
A 0-for-9 record on 30-day alpha doesn't mean Evans trades on information. It means, specifically, that the stocks he sold kept going up after he sold them. That could mean a lot of things: tax-loss harvesting at the wrong time, a financial advisor with unfortunate timing, simple bad luck spread across nine small positions, or portfolio rebalancing that happened to coincide with market moves. The disclosure system tells you what was sold and when. It doesn't tell you why.
What it does tell you is that if you'd done the opposite of every Evans sale in the scored sample, you'd have outperformed the S&P 500 by an average of 5.1 percentage points over the 30 days following each trade. Across nine trades. Consistently, not occasionally.
It's a data observation. A striking one, but a data observation.
Evans represents Pennsylvania's 3rd congressional district, centered on Philadelphia. He's served since 2016. His Ways and Means seat gives him a front-row view of tax legislation, trade policy, and healthcare financing. His full disclosure record at Blind Trust shows the complete trade history the law requires him to file.
The receipts are public. Make of them what you make of them.